-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
RSV604
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/676128-63-5.gif)
| Category | Respiratory syncytial Virus (RSV) |
| CAS | 676128-63-5 |
| Description | RSV604 is a a novel benzodiazepine with submicromolar anti-RSV activity (EC50=0.86 uM). |
Product Information
| Synonyms | RSV-604; A-60444; RSV604; A60444; RSV 604; A 60444; 1-(2-Fluorophenyl)-3-[(3S)-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]urea; |
| IUPAC Name | 1-(2-fluorophenyl)-3-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]urea |
| Molecular Weight | 388.39 |
| Molecular Formula | C22H17FN4O2 |
| Canonical SMILES | c1ccc(cc1)C2=N[C@@H](C(=O)Nc3c2cccc3)NC(=O)Nc4ccccc4F |
| InChI | 1S/C22H17FN4O2/c23-16-11-5-7-13-18(16)25-22(29)27-20-21(28)24-17-12-6-4-10-15(17)19(26-20)14-8-2-1-3-9-14/h1-13,20H,(H,24,28)(H2,25,27,29)/t20-/m1/s1 |
| InChIKey | MTPVBMVUENFFLL-HXUWFJFHSA-N |
| Purity | ≥98% |
| Solubility | Soluble in DMSO |
| Appearance | Solid Powder |
| Application | A putative RSV nucleoprotein(N) inhibitor in phase 2 clinical trials. |
| Shelf Life | As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly |
| Storage | Store at -20 °C |
| Complexity | 634 |
| Exact Mass | 388.13355396 |
| PSA | 82.59000 |
| Target | IC50 value: 0.86 uM(EC50) |
| XLogP3-AA | 3.3 |
